Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention
Open Access
- 1 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 33 (2), 385-393
- https://doi.org/10.1093/carcin/bgr282
Abstract
Studies have shown that fisetin, a small phytochemical molecule, has antitumor activity; however, its antiangiogenic activity has not yet been examined. Accordingly, herein, we investigated the antiangiogenic efficacy and associated mechanisms of fisetin in human umbilical vein endothelial cells (HUVECs). Fisetin (10–50 μM) strongly inhibited the regular serum plus growth supplement- and vascular endothelial growth factor (VEGF)-induced growth (up to 92%, P < 0.001) and survival (up to 16%, P < 0.001) of HUVEC in a dose- and time-dependent manner. Fisetin also caused cell cycle arrest at G 1 (strong) and G 2 /M (moderate) phases together with a decrease in cyclin D1 and an increase in p53 levels. Fisetin-caused cell death was accompanied by decreased expression of survivin and an increase in cleaved levels of caspases-3 and -7 and poly-(ADP-ribose) polymerase along with an increased ratio of Bax to Bcl-2. Furthermore, fisetin inhibited capillary-like tube formation on Matrigel (up to 85%, P < 0.001) as well as migration (up to 66%, P < 0.001), which were associated with decreased expression of endothelial nitric oxide synthase (eNOS) and VEGF in HUVEC. It also decreased the expression of eNOS, VEGF, inducible nitric oxide synthase, matrix metalloproteinase-2 and -9 in A549 and DU145 human cancer cells. In vivo matrigel plug assay in mice showed significant decrease in size (up to 43%, P < 0.001), vascularization and hemoglobin content (up to 94%, P < 0.001) in the plugs from fisetin-treated, compared with control mice. Overall, these results suggest that fisetin inhibits various attributes of angiogenesis, which might contribute to its reported antitumor effects, and therefore, fisetin warrants further investigation for its angiopreventive potential toward cancer control.Keywords
This publication has 41 references indexed in Scilit:
- Tumor angiogenesis – A potential target in cancer chemopreventionFood and Chemical Toxicology, 2008
- Cancer Chemoprevention Through Dietary Antioxidants: Progress and PromiseAntioxidants and Redox Signaling, 2008
- Molecular Pathways for Cancer AngiopreventionClinical Cancer Research, 2007
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agentsThe FASEB Journal, 2002
- Angiogenesis in cancer and other diseasesNature, 2000
- Combinations for cancer preventionNature Medicine, 2000
- Chemoprevention of cancerCarcinogenesis: Integrative Cancer Research, 2000
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971